Evidence map›Paper›PMID 36163081›Full record

ArticleMilitary Medical Research2022

Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability.

Zhi-Qiang Ma, Ying-Tong Feng, Kai Guo, Dong Liu, Chang-Jian Shao, Ming-Hong Pan, Yi-Meng Zhang, Yu-Xi Zhang, Di Lu, Di Huang and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Military Medical Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. HDAC7 promotes ovarian cancer malignancy via AKT/mTOR signalling pathway.Journal of cellular and molecular medicine · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Zhi-Qiang Ma *Department of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Ying-Tong Feng *Department of Thoracic Surgery, Tangdu Hospital, the Fourth Military Medical University, Xi'an, 710038, China.
Kai Guo *Department of Thoracic Surgery, Tangdu Hospital, the Fourth Military Medical University, Xi'an, 710038, China.
Dong Liu *State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100037, China.
Chang-Jian ShaoDepartment of Thoracic Surgery, Tangdu Hospital, the Fourth Military Medical University, Xi'an, 710038, China.
Ming-Hong PanDepartment of Thoracic Surgery, Tangdu Hospital, the Fourth Military Medical University, Xi'an, 710038, China.
Yi-Meng ZhangDepartment of Ophthalmology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, 710038, China.
Yu-Xi ZhangDepartment of Cardiovascular Surgery, Xijing Hospital, the Fourth Military Medical University, Xi'an, 710032, China.
Di LuDepartment of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Di HuangDepartment of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Fan ZhangDepartment of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Jin-Liang WangDepartment of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Bo YangDepartment of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Jing HanDepartment of Ophthalmology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, 710038, China. hanjing@fmmu.edu.cn.
Xiao-Long YanDepartment of Thoracic Surgery, Tangdu Hospital, the Fourth Military Medical University, Xi'an, 710038, China. yanxiaolong@fmmu.edu.cn.
Yi HuDepartment of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. huyi301zlxb@sina.com.ORCID 0000-0001-9319-5692
Chinese PLA General Hospital · CNAir Force Medical University · CNTang Du Hospital · CNXijing Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNShaanxi Provincial People's Hospital · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMelatonin, a natural hormone secreted by the pineal gland, has been reported to exhibit antitumor properties through diverse mechanisms of action. However, the oncostatic function of melatonin on esophageal squamous cell carcinoma (ESCC) remains elusive. This study was conducted to investigate the potential effect and underlying molecular mechanism of melatonin as single anticancer agent against ESCC cells.

methodsESCC cell lines treated with or without melatonin were used in this study. In vitro colony formation and EdU incorporation assays, and nude mice tumor xenograft model were used to confirm the proliferative capacities of ESCC cells. RNA-seq, qPCR, Western blotting, recombinant lentivirus-mediated target gene overexpression or knockdown, plasmids transfection and co-IP were applied to investigate the underlying molecular mechanism by which melatonin inhibited ESCC cell growth. IHC staining on ESCC tissue microarray and further survival analyses were performed to explore the relationship between target genes' expression and prognosis of ESCC.

resultsMelatonin treatment dose-dependently inhibited the proliferative ability and the expression of histone deacetylase 7 (HDAC7), c-Myc and ubiquitin-specific peptidase 10 (USP10) in ESCC cells (P < 0.05). The expressions of HDAC7, c-Myc and USP10 in tumors were detected significantly higher than the paired normal tissues from 148 ESCC patients (P < 0.001). Then, the Kaplan-Meier survival analyses suggested that ESCC patients with high HDAC7, c-Myc or USP10 levels predicted worse overall survival (Log-rank P < 0.001). Co-IP and Western blotting analyses further revealed that HDAC7 physically deacetylated and activated β-catenin thus promoting downstream target c-Myc gene transcription. Notably, our mechanistic study validated that HDAC7/β-catenin/c-Myc could form the positive feedback loop to enhance ESCC cell growth, and USP10 could deubiquitinate and stabilize HDAC7 protein in the ESCC cells. Additionally, we verified that inhibition of the HDAC7/β-catenin/c-Myc axis and USP10/HDAC7 pathway mediated the anti-proliferative action of melatonin on ESCC cells.

conclusionsOur findings elucidate that melatonin mitigates the HDAC7/β-catenin/c-Myc positive feedback loop and inhibits the USP10-maintained HDAC7 protein stability thus suppressing ESCC cell growth, and provides the reference for identifying biomarkers and therapeutic targets for ESCC.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaMelatoninAnimalsbeta CateninCateninsCell ProliferationFeedbackHistone DeacetylasesHumansMiceMice, NudeProtein StabilityProto-Oncogene Proteins c-mycUbiquitin-Specific ProteasesUbiquitin Thiolesterasebeta CateninCateninsCTNNB1 protein, humanHDAC7 protein, humanHistone DeacetylasesMelatoninMYC protein, humanProto-Oncogene Proteins c-mycUbiquitin-Specific ProteasesUbiquitin ThiolesteraseUSP10 protein, humanc-MycEsophageal squamous cell carcinoma (ESCC)Histone deacetylase 7 (HDAC7)MelatoninUbiquitin-specific peptidase 10 (USP10)β-catenin

Identifiers

PMID36163081
PMCPMC9513894
OpenAlexW4297254369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.